🧬 The Science of Psilocybin

An Interactive Visual Guide to Research, Mechanisms & Therapeutic Applications

📊 Research at a Glance

Key statistics from clinical studies and research

71%
Depression Response Rate
Johns Hopkins, 2022
80%
Reduced End-of-Life Anxiety
NYU Langone, 2016
67%
Smoking Cessation Success
Johns Hopkins, 2014
0
Fatal Overdoses (Pure Psilocybin)
Global Drug Survey
PFC DMN 5-HT2A

How Psilocybin Works

Psilocybin creates profound changes in brain connectivity, opening new pathways for thought and perception.

  • 🧪
    5-HT2A Receptor Binding
    Psilocin binds to serotonin receptors
  • 🔗
    Increased Connectivity
    Brain regions communicate in new ways
  • 🧠
    DMN Suppression
    Default Mode Network becomes less active
  • 🌱
    Neuroplasticity
    Promotes new neural connections

📅 Research Timeline

Key milestones in psilocybin research history

1958
Psilocybin Isolated
Albert Hofmann at Sandoz Labs synthesizes psilocybin from Psilocybe mexicana mushrooms.
1962
Good Friday Experiment
Walter Pahnke conducts the famous study showing psilocybin can induce mystical experiences.
1970
Schedule I Classification
US Controlled Substances Act halts research for decades.
2006
Research Resurgence
Johns Hopkins publishes landmark study on mystical experiences and lasting positive effects.
2018
Breakthrough Therapy
FDA grants Breakthrough Therapy designation for psilocybin in treatment-resistant depression.
2020
Oregon Legalization
Oregon becomes first US state to legalize psilocybin therapy.
2023
Australia Approval
Australia becomes first country to approve psilocybin for depression treatment.

📈 Dose-Response Relationship

Understanding the effects at different dose levels

Microdose 0.1 - 0.3g
Sub-perceptual
Low Dose 0.5 - 1g
Mild effects
Medium Dose 1.5 - 2.5g
Standard psychedelic experience
High Dose 3 - 4g
Strong ego dissolution possible
Heroic Dose 5g+
Intense - experienced users only
💡
Enhanced Creativity
🎨
Visual Changes
💭
Introspection
🌌
Mystical States

🔬 Current Research Areas

Active clinical trials and therapeutic applications

🧠

Treatment-Resistant Depression

Multiple Phase 2b/3 trials showing significant efficacy for depression that hasn't responded to conventional treatments.

Phase 3 Trials
🚭

Addiction Treatment

Promising results for alcohol use disorder and tobacco addiction with 67% smoking cessation rate at 12 months.

Active Research
💔

End-of-Life Anxiety

Helping terminally ill patients cope with existential distress. 80% showed clinically significant reduction in anxiety.

Breakthrough Therapy
🔄

OCD & PTSD

Early-stage research showing potential for obsessive-compulsive disorder and trauma-related conditions.

Early Research
C C C N O P C₁₂H₁₇N₂O₄P

Psilocybin Properties

  • Chemical Formula C₁₂H₁₇N₂O₄P
  • Molecular Weight 284.25 g/mol
  • Classification Tryptamine
  • Primary Target 5-HT2A Receptor
  • Active Form Psilocin (dephosphorylated)
  • Duration 4-6 hours
  • LD50 (mice) 280 mg/kg
  • Therapeutic Index ~1000 (very high)

📚 Scientific Sources

Peer-reviewed research references

Johns Hopkins Center

Griffiths RR, et al. (2016). "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer."

View Study →

Imperial College London

Carhart-Harris RL, et al. (2016). "Neural correlates of the LSD experience revealed by multimodal neuroimaging."

View Study →

COMPASS Pathways

Phase 2b trial data showing significant reduction in depression symptoms with COMP360 psilocybin therapy.

View Research →

📥 Download This Infographic

Get a high-resolution PDF version for educational purposes

Download PDF Version